Van ECK Associates Corp Has $98,000 Position in Alphatec Holdings, Inc. (NASDAQ:ATEC)

Van ECK Associates Corp lowered its position in Alphatec Holdings, Inc. (NASDAQ:ATEC) by 44.4% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 10,722 shares of the medical technology company’s stock after selling 8,551 shares during the period. Van ECK Associates Corp’s holdings in Alphatec were worth $98,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in the company. State Street Corp boosted its position in Alphatec by 10.1% during the third quarter. State Street Corp now owns 3,138,960 shares of the medical technology company’s stock worth $17,453,000 after purchasing an additional 287,350 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its position in Alphatec by 11.3% during the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,928,094 shares of the medical technology company’s stock worth $16,280,000 after purchasing an additional 297,850 shares during the period. Royce & Associates LP boosted its position in Alphatec by 15.9% during the third quarter. Royce & Associates LP now owns 1,212,286 shares of the medical technology company’s stock worth $6,740,000 after purchasing an additional 165,954 shares during the period. Walleye Capital LLC boosted its position in Alphatec by 3.2% during the third quarter. Walleye Capital LLC now owns 1,061,462 shares of the medical technology company’s stock worth $5,902,000 after purchasing an additional 32,529 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its position in Alphatec by 1.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 823,222 shares of the medical technology company’s stock worth $4,577,000 after purchasing an additional 15,577 shares during the period. Institutional investors and hedge funds own 66.35% of the company’s stock.

Alphatec Stock Performance

Shares of NASDAQ ATEC opened at $10.61 on Monday. The business has a fifty day simple moving average of $10.48 and a 200 day simple moving average of $8.26. The company has a current ratio of 2.32, a quick ratio of 1.15 and a debt-to-equity ratio of 30.21. The firm has a market capitalization of $1.50 billion, a price-to-earnings ratio of -8.29 and a beta of 1.43. Alphatec Holdings, Inc. has a one year low of $4.88 and a one year high of $15.69.

Insider Activity at Alphatec

In other Alphatec news, COO Scott Lish sold 27,453 shares of the stock in a transaction on Thursday, February 6th. The stock was sold at an average price of $11.49, for a total transaction of $315,434.97. Following the completion of the transaction, the chief operating officer now directly owns 867,677 shares in the company, valued at $9,969,608.73. This represents a 3.07 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP David Sponsel sold 58,283 shares of the stock in a transaction on Monday, January 13th. The stock was sold at an average price of $10.71, for a total value of $624,210.93. Following the transaction, the executive vice president now owns 502,311 shares of the company’s stock, valued at $5,379,750.81. This represents a 10.40 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 222,376 shares of company stock worth $2,557,148. 22.80% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on ATEC shares. HC Wainwright reissued a “buy” rating and issued a $20.00 price objective on shares of Alphatec in a research report on Tuesday, January 14th. Needham & Company LLC increased their price objective on Alphatec from $13.00 to $16.00 and gave the company a “buy” rating in a research report on Monday, January 13th. Finally, Barclays increased their price objective on Alphatec from $20.00 to $21.00 and gave the company an “overweight” rating in a research report on Wednesday, January 22nd. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $17.56.

Alphatec Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.